PanTheryx has launched Relesium, a patented supplement formulated to relieve the negative side effects of GLP-1 medications.
This includes popular weight management and type II diabetes drugs, such as Ozempic, Wegovy, Mounjaro and other semaglutides.
The chicken egg powder and bovine colostrum ingredient, according to PanTheryx, is a natural solution that can address digestive discomfort, nausea, bloating and irregular bowel movements — which are commonly associated with those taking GLP-1 medications.
Scientifically backed solutions for GLP-1 medication users
A recent publication has highlighted the positive impacts of Relesium in supporting gut health, while also helping GLP-1 drug users to mitigate the common side effects associated with the drug.
The review, written by gastroenterologist and scientific advisor for PanTheryx, Raymond Playford, brings together the growing body of research on both chicken egg powder and bovine colostrum.
According to Dr Playford, both functional ingredients can help to stabilise the gut, with their efficacy being most apparent when used in combination owing to their synergistic effects.
Raymond commented: "the combination of egg and bovine colostrum not only supports gut stability, but also delivers high-quality protein and essential micronutrients."
"Vitamins, minerals and antioxidants are particularly important for GLP-1 users who may experience reduced appetite, fatigue and energy loss. The ingredients also contain prebiotics, which can help a user to support their microbiome, as well as several other factors such as immunoglobulins and antimicrobial peptides. This helps to prevent the adhesion of microbes to gut surfaces and neutralise toxins and viruses."
To build on these findings, PanTheryx has also commissioned a observational pilot study, which will explore Relesium's efficacy in patients taking GLP-1 medications.
Eighteen participants using GLP-1 medications enrolled in the study, ten of which experienced gastrointestinal symptoms and were administered Relesium.
Initial results are promising, showing that all ten reported notable improvement and reduction in gut-related symptoms after adding Relesium to their regimen. A placebo-controlled trial is planned to further validate Relesium’s efficacy.
Catering to the GLP-1 patient population
As GLP-1 medications surge in popularity for the overweight and obese population, as well as for those with diabetes and other health conditions, an opportunity has opened up in the market.
With one in eight Americans now relying on these drugs, and around 50% of patients reporting side effects, PanTheryx believes there is a need to provide solutions for this patient population to allow them to continue treatment as comfortably as possible.
To widely cater to the demand for natural and effective solutions, PanTheryx aims to make this solution widely available, explains CEO Tom Feeley: "Relesium is entering a largely untapped market addressing the need for all-natural, fast-acting solutions to alleviate gastrointestinal discomfort."
"This ingredient nw allows health and wellness companies to offer their customers a science-backed product that addresses these challenges without compromising the effectiveness of their GLP-1 therapy and additional medications."
Relesium is launching in powder format, which can be used as a standalone supplement or within other product formulations starting January 2025. Additional formats and formulations are under development for future applications.
